Chau T. Dang, MD, discusses the rationale of the phase 2 BERENICE trial in early-stage HER2-positive breast cancer.
Chau Dang, MD, Memorial Sloan Kettering Westchester
Advertisement
Articles by Chau Dang, MD, Memorial Sloan Kettering Westchester
Advertisement
Latest Updated Articles
Q&A: Practical Considerations in HER2+ Breast CancerSeptember 24th 2020
Dual HER2-Targeted Approaches in Breast CancerSeptember 24th 2020
The Impact of Subcutaneous Option for HER2+ BCSeptember 24th 2020
Efficacy of Fixed-Dose Subcutaneous Therapy for HER2+ BCSeptember 24th 2020
Historic Perspectives on HER2+ Breast CancerSeptember 24th 2020
Administration of Dual HER2-Targeted Therapy in BCSeptember 24th 2020
Advertisement
Advertisement
Trending on OncLive
1
Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma
2
Bexobrutideg Could Pave the Way for BTK Degraders in R/R Chronic Lymphocytic Leukemia
3
Extended FOLFOX, Atezolizumab Duration Linked With Improved DFS in Stage III dMMR Colon Cancer
4
ESR1 Mutations Steer the Oral SERD Story in Breast Cancer: With Sara Nunnery, MD, MSCI; and MinhTri Nguyen, MD
5